Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brazikumab in Moderately to Severely Active Ulcerative Colitis (Expedition Lead-in)
jRCT2011210030Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial of brazikumab in autoimmune colitis and inflammatory bowel disease (IBD) (3 arms), sponsored by AstraZeneca. Primary endpoint: Clinical remission based on modified Mayo score (mMS) at Week 10. Started Jan 2022; status: completed.
02
Drugs
brazikumab
03
Conditions
autoimmune colitisinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on jRCT2011210030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011210030.